Core Viewpoint - The company Innotech has identified a range of home testing products that align well with current market demands, particularly in the context of respiratory and gastrointestinal infections, and is actively collaborating with major e-commerce platforms to enhance market presence [2]. Product Offerings - Innotech's product lineup includes: - Influenza A and B virus antigen test kits (colloidal gold method) - New coronavirus (2019-nCoV) antigen test kits (latex method) - Respiratory syncytial virus, adenovirus, parainfluenza virus antigen combination test kits (latex chromatography method) - Group A rotavirus, adenovirus, norovirus antigen test kits (latex chromatography method) - Fecal occult blood (FOB) test kits (colloidal gold immunochromatography method) - Helicobacter pylori antigen test kits (latex method) [2]. Market Development - The home testing market is experiencing rapid growth, driven by improvements in regulatory frameworks and clinical guidelines, indicating a promising application market for home testing products [2]. E-commerce Collaboration - The company has established partnerships with major e-commerce platforms such as JD.com, Tmall, and Meituan by setting up official flagship stores to enhance product accessibility [2].

Core Viewpoint - The company, Beijing Innotech Biotechnology Co., Ltd., has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Investors" action plan to optimize operations, standardize governance, and actively return to investors, reflecting confidence in future development and recognition of company value [1]. Group 1: Business Optimization - The company has established a comprehensive R&D organizational structure with six major technology platforms, including immunochromatography, indirect immunofluorescence, liquid phase immunoassay, nucleic acid molecular detection, recombinant protein engineering, and cell and pathogen culture platforms, while also introducing a super-sensitive immunoassay technology platform based on single-molecule detection [1]. - During the reporting period, the company maintained R&D investment across all major technology platforms [1]. Group 2: Product Development - The company obtained new product registration certificates for various testing kits in the domestic market, including PCR kits for influenza viruses and respiratory syncytial virus, and became one of the few companies with both antigen and nucleic acid testing products [2]. - In the international market, the company expanded its product matrix in Southeast Asia and achieved CE (IVDR) product registration for self-testing kits in Europe, marking a breakthrough in the C-end business [2]. - The company received FDA 510(k) product registration for influenza antigen testing kits in the U.S. market, laying a crucial foundation for entering the U.S. market [2]. Group 3: Corporate Governance - Since its IPO in 2022, the company has continuously improved its governance structure in compliance with relevant laws and regulations, ensuring standardized operations and protecting the interests of all shareholders, especially minority shareholders [3]. Group 4: Investor Communication - The company emphasizes information disclosure and maintains close communication with investors through various channels, including on-site research, online communication meetings, and social media, to convey the company's long-term investment value [3]. Group 5: Shareholder Returns - The company has established clear regulations regarding profit distribution, including cash dividend policies, and has implemented a stable and sustainable cash dividend distribution [4]. - In 2024, the company distributed cash dividends of 5.60 yuan per 10 shares, totaling 75,233,455.36 yuan, and has cumulatively distributed cash dividends of 152,243,877.22 yuan since its listing, accounting for 79.92% of the average net profit during this period [4]. Group 6: Future Actions - The company will continue to evaluate the specific measures of the "Quality Improvement, Efficiency Enhancement, and Return to Investors" action plan and fulfill its information disclosure obligations [5].